Akebia Therapeutics (AKBA) Common Equity (2013 - 2026)
Akebia Therapeutics' Common Equity was $25.02 million in Q2 2026, down 14.4% from $29.22 million a year earlier and down 8.6% from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Akebia Therapeutics came in at $32.61 million.
- Common Equity shows a five-year compound annual growth rate of -33.2% (FY2020 to FY2025).
- In earlier years, Common Equity was -$49.19 million in FY2024, -$30.58 million in FY2023, $5.23 million in FY2022 (-92.9%) and $74.01 million in FY2021 (-69.7%).
- The Q2 2026 figure marks the lowest quarterly Common Equity since Q1 2025.
- The best year-over-year quarter for Common Equity over five years was Q1 2026 (growth of 11.4%); the worst was Q3 2022 (a decline of 94.0%).
- Per Business Quant data, AKBA's Common Equity in the three quarters before Q2 2026 was $27.38 million (Q1 2026), $32.61 million (Q4 2025) and $41.59 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,133.15 Bn | 1,101.73 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 616.41 Bn | 534.94 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 501.01 Bn | 474.12 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 367.15 Bn | 321.53 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 298.00 Bn | 261.99 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.56 Bn | 235.25 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 235.40 Bn | 190.80 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 190.38 Bn | 164.57 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 169.76 Bn | 116.40 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Akebia Therapeutics | 156.56 Mn | -512.92 Mn | 38.70 Mn | 25.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.02 Mn |
| Mar 31, 2026 | 27.38 Mn |
| Dec 31, 2025 | 32.61 Mn |
| Sep 30, 2025 | 41.59 Mn |
| Jun 30, 2025 | 29.22 Mn |
| Mar 31, 2025 | 24.58 Mn |
| Dec 31, 2024 | -49.19 Mn |
| Sep 30, 2024 | -50.40 Mn |
| Jun 30, 2024 | -33.75 Mn |
| Mar 31, 2024 | -27.26 Mn |
| Dec 31, 2023 | -30.58 Mn |
| Sep 30, 2023 | -39.42 Mn |
| Jun 30, 2023 | -26.81 Mn |
| Mar 31, 2023 | -19.12 Mn |
| Dec 31, 2022 | 5.23 Mn |
| Sep 30, 2022 | 8.26 Mn |
| Jun 30, 2022 | 58.94 Mn |
| Mar 31, 2022 | 22.58 Mn |
| Dec 31, 2021 | 74.01 Mn |
| Sep 30, 2021 | 137.15 Mn |
API Access
Akebia Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();